双雄联手破局 Enhertu 重构乳腺癌治疗版图

新浪财经
Oct 19, 2025

(来源:抗体圈)摘要:阿斯利康与第一三共联合打造的 HER2 靶向 ADC 药物 Enhertu,近期在早期乳腺癌 III 期临床试验中斩获佳绩。其序贯 THP 方案不仅显著提升高风险患者的病理完全缓解率,更构建起覆盖 "新辅助 - 辅助 - 晚期" 的全病程治疗体系,正对罗氏长期主导的 HER2 阳性乳腺癌治疗标准发起全面冲击,开启 ADC 药物定义治疗规则的新时代。临床突破:新辅助治疗再下一城...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10